Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Hypersensitivity, Immediate

Subtypes of Hypersensitivity, Immediate

Food Allergy 10 Anaphylaxis 8 Hereditary Angioedema 5 Allergic conjunctivitis 3 Cow's milk allergy 3 Urticaria 3 Allergic Bronchopulmonary Aspergillosis 2 Allergic Fungal Rhinosinusitis 1 Angioedema 1

34 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypersensitivity, Immediate

10 trials tracked for Hypersensitivity, Immediate: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 120 citations.

10Trials tracked

3Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 3 3 Phase 2 6 Other / NA 1

Phase 3 Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed · 120 cited
Phase 3 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects Completed · 14 cited
Phase 3 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Completed · 3 cited
Phase 2 Effect of Benralizumab in Atopic Dermatitis Completed
Phase 2 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Completed
Phase 2 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Completed

Show 4 more trials

Phase 2 Oral Immunotherapy for Childhood Egg Allergy Completed
Phase 2 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed
Phase 2 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Completed
N/A Asthma Data Innovation Demonstration Project Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hypersensitivity, Immediate: what the trials found

Dupilumab demonstrated significant efficacy in improving skin symptoms for patients with hypersensitivity. At week 16, a high percentage of participants achieved an Investigator's Global Assessment (IGA) score of 0 or 1 with a reduction of at least 2 points compared to baseline ¹. Additionally, treatment resulted in a significant reduction in Eczema Area and Severity Index (EASI) scores by approximately 64.8% to 65.9% at week 16 ¹.

PF-04965842 100 mg showed clinical efficacy in improving skin conditions and reducing pruritus. At week 12, a significant percentage of patients achieved an IGA response of clear or almost clear (0 or 1) with at least a 2-point reduction from baseline ³. Furthermore, there was a statistically significant improvement in the Numerical Rating Scale (NRS) for the severity of pruritus across multiple time points up to week 16 ³.

Evidence regarding the durability of response for PF-04965842 100 mg indicates that treatment significantly extended the time to loss of response compared to placebo. The median time to first loss of response (IGA score of 2 or higher) was notably longer in the treatment group ².

Recent results — preliminary, needs further review

Benralizumab was evaluated in a Phase 2 trial for this condition ⁴.
Tezepelumab showed changes in airway submucosal inflammatory cells and reticular basement membrane thickness, though these findings are not yet corroborated ⁵.
Peanut powder intervention showed increases in IgG4 levels at 6 months compared to baseline ⁶.
Placebo Viaskin® Patch was associated with a higher percentage of successful treatment responses and desensitization to peanut protein compared to placebo ⁷.
Glycerinated peanut allergenic extract resulted in a significantly higher percentage of participants successfully consuming 5,000 mg of peanut powder compared to the control group ⁸.

For the clinician treating this condition

Dupilumab is established as effective for reducing EASI scores and improving IGA ratings at 16 weeks ¹.
PF-04965842 100 mg is associated with significant improvements in pruritus severity and skin clearance at 12 weeks ³.
Treatment with PF-04965842 100 mg is associated with a prolonged duration of clinical response compared to placebo ².

AI synthesis of 8 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

‹ Prev 1 2 3 Next ›